# A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).

> **NCT07729371** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sapience Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- Familial Adenomatous Polyposis (FAP)

## Interventions

- **DRUG:** ST316 IV
- **DRUG:** ST316 IV

## Key facts

- **NCT ID:** NCT07729371
- **Lead sponsor:** Sapience Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-04
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729371, "A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*